Premium
lncRNA TUC338 is a potential diagnostic biomarker for bladder cancer
Author(s) -
Li Gang,
Zhang Yang,
Mao Jing,
Hu Peng,
Chen Qiang,
Ding Wei,
Pu Rong
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.29104
Subject(s) - bladder cancer , downregulation and upregulation , oncogene , microrna , cancer , biomarker , medicine , cancer research , long non coding rna , stage (stratigraphy) , oncology , pathology , biology , cell cycle , gene , biochemistry , paleontology
Abstract Although long noncoding RNA TUC338 has been characterized as an oncogene, its role in bladder cancer is unknown. The purpose of the present study is to investigate the function of TUC338 in bladder cancer. We found that TUC338 was upregulated in early‐stage bladder cancer patients and showed early diagnostic values. After surgical resection, plasma levels of TUC338 were significantly downregulated. Moreover, microRNA 10b (miR‐10b) was also upregulated in bladder cancer patients. TUC338 and miR‐10b were positive and significantly correlated in bladder cancer patients, but not in healthy controls. Bladder cancer cells with TUC338 overexpression showed upregulated miR‐10b, while miR‐10b overexpression failed to significantly affect TUC338. TUC338 and miR‐10b overexpression significantly promoted bladder cancer cell invasion and migration. Therefore, TUC338 may promote bladder cancer at least partially by upregulating miR‐10b.